SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited (SMSPHARMA.NS) Stock Competitors & Peer Comparison
See (SMSPHARMA.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMSPHARMA.NS | ₹358.00 | +0.00% | 34.9B | 37.17 | ₹10.02 | +0.11% |
| CIPLA.BO | ₹1,329.05 | +0.00% | 1.1T | 23.87 | ₹56.20 | +1.19% |
| CIPLA.NS | ₹1,328.90 | +0.00% | 1.1T | 23.82 | ₹56.29 | +1.19% |
| ABBOTINDIA.NS | ₹26,395.00 | +0.00% | 558.8B | 36.67 | ₹717.07 | +1.81% |
| ABBOTINDIA.BO | ₹26,389.45 | +0.00% | 558.1B | 36.97 | ₹710.49 | +1.81% |
| GLAXO.BO | ₹2,571.10 | -0.00% | 440.5B | 46.18 | ₹56.30 | +2.08% |
| GLAXO.NS | ₹2,577.90 | +0.00% | 439.9B | 43.18 | ₹60.14 | +2.08% |
| GLAND.NS | ₹1,840.50 | +0.00% | 300.1B | 35.43 | ₹51.42 | +0.99% |
| GLAND.BO | ₹1,836.25 | +0.00% | 300B | 35.46 | ₹51.35 | +0.99% |
| PFIZER.BO | ₹4,993.30 | +0.00% | 225.9B | 26.93 | ₹183.33 | +3.35% |
Stock Comparison
SMSPHARMA.NS vs CIPLA.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while CIPLA.BO trades at ₹1,329.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas CIPLA.BO's P/E ratio is 23.87. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to CIPLA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check CIPLA.BO's competition here
SMSPHARMA.NS vs CIPLA.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while CIPLA.NS trades at ₹1,328.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas CIPLA.NS's P/E ratio is 23.82. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to CIPLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check CIPLA.NS's competition here
SMSPHARMA.NS vs ABBOTINDIA.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, ABBOTINDIA.NS has a market cap of 558.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while ABBOTINDIA.NS trades at ₹26,395.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas ABBOTINDIA.NS's P/E ratio is 36.67. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to ABBOTINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check ABBOTINDIA.NS's competition here
SMSPHARMA.NS vs ABBOTINDIA.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, ABBOTINDIA.BO has a market cap of 558.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while ABBOTINDIA.BO trades at ₹26,389.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas ABBOTINDIA.BO's P/E ratio is 36.97. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to ABBOTINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check ABBOTINDIA.BO's competition here
SMSPHARMA.NS vs GLAXO.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, GLAXO.BO has a market cap of 440.5B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while GLAXO.BO trades at ₹2,571.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas GLAXO.BO's P/E ratio is 46.18. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to GLAXO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAXO.BO's competition here
SMSPHARMA.NS vs GLAXO.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, GLAXO.NS has a market cap of 439.9B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while GLAXO.NS trades at ₹2,577.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas GLAXO.NS's P/E ratio is 43.18. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to GLAXO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAXO.NS's competition here
SMSPHARMA.NS vs GLAND.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, GLAND.NS has a market cap of 300.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while GLAND.NS trades at ₹1,840.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas GLAND.NS's P/E ratio is 35.43. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to GLAND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAND.NS's competition here
SMSPHARMA.NS vs GLAND.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, GLAND.BO has a market cap of 300B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while GLAND.BO trades at ₹1,836.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas GLAND.BO's P/E ratio is 35.46. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to GLAND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check GLAND.BO's competition here
SMSPHARMA.NS vs PFIZER.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, PFIZER.BO has a market cap of 225.9B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while PFIZER.BO trades at ₹4,993.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas PFIZER.BO's P/E ratio is 26.93. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to PFIZER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check PFIZER.BO's competition here
SMSPHARMA.NS vs PFIZER.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, PFIZER.NS has a market cap of 225.6B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while PFIZER.NS trades at ₹4,991.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas PFIZER.NS's P/E ratio is 26.45. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to PFIZER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check PFIZER.NS's competition here
SMSPHARMA.NS vs SANOFICONR.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, SANOFICONR.NS has a market cap of 93.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while SANOFICONR.NS trades at ₹4,056.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas SANOFICONR.NS's P/E ratio is 42.71. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SANOFICONR.NS's ROE of +0.82%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to SANOFICONR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SANOFICONR.NS's competition here
SMSPHARMA.NS vs SANOFI.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, SANOFI.BO has a market cap of 92.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while SANOFI.BO trades at ₹4,025.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas SANOFI.BO's P/E ratio is 26.07. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SANOFI.BO's ROE of +0.42%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to SANOFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SANOFI.BO's competition here
SMSPHARMA.NS vs SANOFI.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, SANOFI.NS has a market cap of 92.7B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while SANOFI.NS trades at ₹4,024.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas SANOFI.NS's P/E ratio is 25.92. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SANOFI.NS's ROE of +0.42%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to SANOFI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SANOFI.NS's competition here
SMSPHARMA.NS vs MARKSANS.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, MARKSANS.BO has a market cap of 80.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while MARKSANS.BO trades at ₹177.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas MARKSANS.BO's P/E ratio is 22.99. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to MARKSANS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check MARKSANS.BO's competition here
SMSPHARMA.NS vs MARKSANS.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, MARKSANS.NS has a market cap of 80.8B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while MARKSANS.NS trades at ₹176.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas MARKSANS.NS's P/E ratio is 22.44. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to MARKSANS.NS's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to MARKSANS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check MARKSANS.NS's competition here
SMSPHARMA.NS vs SENORES.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, SENORES.NS has a market cap of 37.3B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while SENORES.NS trades at ₹815.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas SENORES.NS's P/E ratio is 31.49. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to SENORES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SENORES.NS's competition here
SMSPHARMA.NS vs SMSPHARMA.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, SMSPHARMA.BO has a market cap of 34.9B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while SMSPHARMA.BO trades at ₹357.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas SMSPHARMA.BO's P/E ratio is 37.22. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to SMSPHARMA.BO's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to SMSPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check SMSPHARMA.BO's competition here
SMSPHARMA.NS vs NGLFINE.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, NGLFINE.NS has a market cap of 14.5B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while NGLFINE.NS trades at ₹2,257.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas NGLFINE.NS's P/E ratio is 40.93. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to NGLFINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check NGLFINE.NS's competition here
SMSPHARMA.NS vs NGLFINE.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, NGLFINE.BO has a market cap of 14.5B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while NGLFINE.BO trades at ₹2,260.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas NGLFINE.BO's P/E ratio is 40.92. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.NS is less volatile compared to NGLFINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check NGLFINE.BO's competition here
SMSPHARMA.NS vs TTKHLTCARE.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, TTKHLTCARE.NS has a market cap of 13.1B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while TTKHLTCARE.NS trades at ₹926.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas TTKHLTCARE.NS's P/E ratio is 21.85. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to TTKHLTCARE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check TTKHLTCARE.NS's competition here
SMSPHARMA.NS vs KOPRAN.NS Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, KOPRAN.NS has a market cap of 6.3B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while KOPRAN.NS trades at ₹134.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas KOPRAN.NS's P/E ratio is 38.01. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to KOPRAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check KOPRAN.NS's competition here
SMSPHARMA.NS vs KOPRAN.BO Comparison February 2026
SMSPHARMA.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.NS stands at 34.9B. In comparison, KOPRAN.BO has a market cap of 6.3B. Regarding current trading prices, SMSPHARMA.NS is priced at ₹358.00, while KOPRAN.BO trades at ₹134.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.NS currently has a P/E ratio of 37.17, whereas KOPRAN.BO's P/E ratio is 38.00. In terms of profitability, SMSPHARMA.NS's ROE is +0.14%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.NS is more volatile compared to KOPRAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.NS.Check KOPRAN.BO's competition here